CDK19

Chr 6AD

cyclin dependent kinase 19

Also known as: CDC2L6, CDK11, DEE87, EIEE87, bA346C16.3

This gene encodes a protein that is one of the components of the Mediator co-activator complex. The Mediator complex is a multi-protein complex required for transcriptional activation by DNA binding transcription factors of genes transcribed by RNA polymerase II. The protein encoded by this gene is similar to cyclin-dependent kinase 8 which can also be a component of the Mediator complex. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2014]

OMIMResearchGenerating clinical summary…
MultiplemechanismADLOEUF 0.161 OMIM phenotype
Clinical SummaryCDK19
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
9 unique Pathogenic / Likely Pathogenic· 70 VUS of 113 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.16LOEUF
pLI 1.000
Z-score 4.82
OE 0.03 (0.010.16)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
3.56Z-score
OE missense 0.40 (0.350.47)
114 obs / 282.5 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?
LoF OE?0.03 (0.010.16)
00.351.4
Missense OE?0.40 (0.350.47)
00.61.4
Synonymous OE?0.89
01.21.6
LoF obs/exp: 1 / 29.0Missense obs/exp: 114 / 282.5Syn Z: 0.87
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongCDK19-related intellectual disability and epileptic encephalopathyOTHERAD

This gene — mechanism propensity

DN
0.3892th %ile
GOF
0.4085th %ile
LOF
0.79top 5%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to loss-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · 1 literature citation · LOEUF 0.16
DN1 literature citation

Literature Evidence

DNHowever, in vivo functional expression studies in Drosophila showed that the mutant protein localized normally to the perinuclear region in neurons, and that the mutation resulted in a loss-of-function effect acting in a dominant-negative manner.1
LOFQuantitative PCR of the CDK19 transcript from Epstein-Barr virus-transformed lymphoblastoid cell lines of the patient revealed ~50% reduction in the transcript (p = 0.02), suggesting haploinsufficiency of the gene.2

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

113 submitted variants in ClinVar

Classification Summary

Pathogenic4
Likely Pathogenic5
VUS70
Likely Benign14
Conflicting2
4
Pathogenic
5
Likely Pathogenic
70
VUS
14
Likely Benign
2
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
4
0
0
4
Likely Pathogenic
0
4
1
0
5
VUS
5
61
4
0
70
Likely Benign
0
2
3
9
14
Benign
0
0
0
0
0
Conflicting
2
Total5718995

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

18 pathogenic / likely-pathogenic (of 29) ClinVar copy-number / structural variants overlap CDK19 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

CDK19 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →